Individualized duration of adjuvant alectinib therapy and rechallenge efficacy in ALK-positive non-small cell lung cancer: a case report

BackgroundAnaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is a distinct molecular subtype of cancer that typically affects younger patients and carries a high risk of central nervous system (CNS) metastases. Adjuvant alectinib therapy has demonstrated efficacy in prolo...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Junliang Chen, Yingni Lian, Yu Lan, Chengye Chen, Jun Chen, Zihan Zeng, Simin Feng, Meihan Wang, Tinghua Gao
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2026-04-01
Reeks:	Frontiers in Medicine
Onderwerpen:	adjuvant therapy duration alectinib ALK-rearranged NSCLC CNS metastasis rechallenge efficacy
Online toegang:	https://www.frontiersin.org/articles/10.3389/fmed.2026.1746932/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!